FRI605 Inhibition Of Intestinal SGLT1 With Mizagliflozin For The Treatment Of Post-bariatric Hypoglycemia

Disclosure: H.M. Lawler: Grant Recipient; Self; Vogenx, Inc. T.L. McLaughlin: Advisory Board Member; Self; January AI. Grant Recipient; Self; Eli Lilly & Company, Merck, Vogenx, Inc. Stock Owner; Self; January AI, Eiger BioPharmaceuticals. S. Shakeri: None. E.F. Stortz: None. A. Gupta: None. V....

Descripción completa

Detalles Bibliográficos
Autores principales: Margaret Lawler, Helen, McLaughlin, Tracey L, Shakeri, Soroush, Frederick Stortz, Ethan, Gupta, Aanchal, Singh, Vatsala, Turk, Nicole, Walker, Susan, Cheatham, Bentley, Wilkison, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554770/
http://dx.doi.org/10.1210/jendso/bvad114.829

Ejemplares similares

Ejemplares similares